Physician profile

Tyler Woolum

Emergency Medicine · Oklahoma City, OK

NPI 1669094579

$1,359.47

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$455.26

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Astrazeneca Pharmaceuticals LP $540.90 2021-2024 Andexxa
Janssen Pharmaceuticals, INC $180.02 2022-2023 Xarelto
Inari Medical, INC. $139.24 2023 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Abbvie INC. $98.31 2024
Alexion Pharmaceuticals, INC. $97.91 2022
Csl Behring $97.76 2023 Kcentra
E.R. Squibb & Sons, L.L.C. $55.92 2022
Merck Sharp & Dohme LLC $12.90 2023 Dificid, Zerbaxa

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Tyler Woolum

$1,359.47

in general payments reported 2019-2025

Years
2021-2024
Top company
Astrazeneca Pharmaceuticals LP

https://glasscript.com/doctor/11283474/tyler-woolum

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.